🇪🇺 Duavee in European Union

EMA authorised Duavee on 17 April 2009

Marketing authorisations

EMA — authorised 17 April 2009

  • Application: EMEA/H/C/000913
  • Marketing authorisation holder: Pfizer Europe MA EEIG
  • Local brand name: Conbriza
  • Indication: Conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. When determining the choice of Conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
  • Status: approved

Read official source →

EMA — authorised 11 June 2010

  • Application: EMEA/H/C/001237
  • Marketing authorisation holder: Wyeth Europa Ltd
  • Local brand name: Brilence
  • Status: withdrawn

Read official source →

Duavee in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Bone approved in European Union

Frequently asked questions

Is Duavee approved in European Union?

Yes. EMA authorised it on 17 April 2009; EMA authorised it on 11 June 2010.

Who is the marketing authorisation holder for Duavee in European Union?

Pfizer Europe MA EEIG holds the EU marketing authorisation.